According to the recent research report titled ‘Cystic Fibrosis Therapeutics Market Size By Treatment Method (Medications [Drug Class {CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements}, Route of Administration {Oral Drugs, Inhaled drugs}], Devices), By Distribution Channel (Hospitals, Retail Pharmacies), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with MarketStudyReport, global cystic fibrosis therapeutics market is projected to showcase a robust CAGR over 2021-2027.
 

Rising awareness and adoption of novel treatment procedures in developing regions, along with rise in incidence of cystic fibrosis is driving global cystic fibrosis therapeutics market growth.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4357556/
 

For those unfamiliar, cystic fibrosis (CF) is a hereditary disorder that causes recurring and chronic lung infections in patients. Mutations in the CFTR gene leads to the protein to becoming dysfunctional in CF patients. This illness causes glands to generate sticky, thick mucus and sweat, which clogs airways and damages organs.
 

Elaborating on the Covid-19 impact, the pandemic encouraged the development of novel treatments for several lung infections and illnesses. Increasing scientific researches conducted by medical laboratories have led to market expansion worldwide.
 

Based on treatment type, devices segment held 9% of the overall cystic fibrosis therapeutics market share in 2020 and is expected to expand further by 2027, owing to surging demand for devices to treat the ailment.
 

As per distribution channel, retail pharmacies segment accounted for 30% industry share in 2020 and is projected to showcase optimistic growth over the next years, attributable to rising prevalence of retail pharmacies in developed nations.
 

Geographically, North America market was worth USD 6 billion in 2020 and is predicted to amass notable gains by the end of 2027, on account of increasing number of CF patients in the region.
 

Coming to the competitive landscape, Chiesi Farmaceutici S.p.A., Gilead Sciences Inc., Horizon Therapeutics plc, Viatris Inc., AbbVie, Nestle Health Science, Roche, and Vertex Pharmaceuticals Incorporated are among the key players powering global cystic fibrosis therapeutics industry trends.
 

Notably, industry players are developing new goods, forming strategic collaborations, and implementing acquisitions to amplify profit. For instance, Pharmaxis Ltd., an Australian pharmaceutical business, announced in March 2021 that their cystic fibrosis therapy, Bronchitol, had been released in the United States by Chiesi USA, Ltd., a major pharmaceutical corporation. This helped Pharmaxis get a total payment of USD 10 million for the stock of Bronchitol that Chiesi is commercializing in the United States.